The Cantor laboratory is interested in further elucidating how dysregulation of normal hematopoietic transcriptional mechanisms contributes to human leukemogenesis. We have a particular interest in early initiating events events in leukemogenesis. This includes proteomic, genomic, epigenetic, and biochemical studies of members of the GATA and RUNX transcription factor families, which are frequently mutated in human leukemias. We have also applied genetic studies of familial leukemia/myelodysplastic predisposition syndromes, such as Familial Platelet Disorder with Propensity to Develop Leukemia (FPD/AML) to identify novel genes involved in human leukemogenesis. Our studies also examine the molecular basis of Down Syndrome Transient Myeloproliferative Disorder (DS-TMD) and Acute Megakaryoblastic Leukemia (DS-AMKL), as well as Juvenile Myelomonocytic Leukemia.